drugset / Trial / NCT02202226

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

NCT02202226

Phase 1 Completed 96 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the tolerability and safety of Lu AF35700 after repeated oral dosing to patients with schizophrenia.

Timeline

Start
2013-01
Primary completion
2015-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF35700 Unknown 5 mg Oral
Subject Lu AF35700 Unknown 30 mg Oral
Subject Lu AF35700 Unknown 75 mg Oral

Indications